JPWO2022147532A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022147532A5 JPWO2022147532A5 JP2023540678A JP2023540678A JPWO2022147532A5 JP WO2022147532 A5 JPWO2022147532 A5 JP WO2022147532A5 JP 2023540678 A JP2023540678 A JP 2023540678A JP 2023540678 A JP2023540678 A JP 2023540678A JP WO2022147532 A5 JPWO2022147532 A5 JP WO2022147532A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 85
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 43
- 239000003814 drug Substances 0.000 claims description 30
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 24
- 239000000562 conjugate Substances 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 239000000611 antibody drug conjugate Substances 0.000 claims description 13
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 6
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims description 6
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 6
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims description 6
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 6
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 6
- 230000008685 targeting Effects 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 206010004593 Bile duct cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 201000007180 bile duct carcinoma Diseases 0.000 claims description 3
- 102000055298 human VTCN1 Human genes 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000009870 specific binding Effects 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 238000006065 biodegradation reaction Methods 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 125000005647 linker group Chemical group 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 7
- 238000011321 prophylaxis Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163133707P | 2021-01-04 | 2021-01-04 | |
| US63/133,707 | 2021-01-04 | ||
| US202163172968P | 2021-04-09 | 2021-04-09 | |
| US63/172,968 | 2021-04-09 | ||
| PCT/US2022/011119 WO2022147532A1 (en) | 2021-01-04 | 2022-01-04 | B7h4-targeted antibody-drug conjugates and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024501894A JP2024501894A (ja) | 2024-01-16 |
| JPWO2022147532A5 true JPWO2022147532A5 (enrdf_load_stackoverflow) | 2025-01-08 |
Family
ID=80222361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023540678A Pending JP2024501894A (ja) | 2021-01-04 | 2022-01-04 | Ｂ７ｈ４ターゲティング抗体－薬物コンジュゲートおよびその使用方法 |
Country Status (13)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3604311A4 (en) | 2017-03-29 | 2021-01-13 | LegoChem Biosciences, Inc. | PYRROLOBENZODIAZEPINE DIMERIC PRECURSOR AND ASSOCIATED LIGAND-BOND CONJUGATE COMPOUND |
| TW202120500A (zh) | 2019-08-02 | 2021-06-01 | 美商梅爾莎納醫療公司 | 干擾素基因刺激蛋白（ｓｔｉｎｇ）激動劑化合物及用途 |
| AU2021248635A1 (en) | 2020-04-02 | 2022-10-27 | Mersana Therapeutics, Inc. | Antibody drug conjugates comprising STING agonists |
| WO2022147532A1 (en) | 2021-01-04 | 2022-07-07 | Mersana Therapeutics, Inc. | B7h4-targeted antibody-drug conjugates and methods of use thereof |
| TW202412853A (zh) | 2022-05-17 | 2024-04-01 | 美商梅爾莎納醫療公司 | 治療癌症之靶定ｂ７－ｈ４之抗體－藥物結合物 |
| WO2024100452A2 (en) * | 2022-11-08 | 2024-05-16 | Legochem Biosciences, Inc. | Heterocyclic compounds as sting agonists |
| WO2024186626A1 (en) * | 2023-03-03 | 2024-09-12 | Bolt Biotherapeutics, Inc. | Aza-bicyclic sting agonist immunoconjugates, and uses thereof |
| WO2025106278A1 (en) | 2023-11-17 | 2025-05-22 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
| CA2510550A1 (en) | 2003-01-10 | 2004-07-29 | Pradman Qasba | Catalytic domains of .beta./1,4)-galactosyltransferase i having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use |
| EP2384767B1 (en) | 2005-03-24 | 2016-03-09 | Millennium Pharmaceuticals, Inc. | Antibodies that bind OV064 and methods of use therefor |
| US8759490B2 (en) | 2005-03-24 | 2014-06-24 | Millennium Pharamaceuticals, Inc. | Antibodies that bind OV064 and methods of use therefor |
| SG163554A1 (en) | 2005-07-01 | 2010-08-30 | Medarex Inc | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| CA2630483C (en) | 2005-12-08 | 2015-05-19 | Medarex, Inc. | Human monoclonal antibodies to o8e |
| US9121853B2 (en) | 2006-03-20 | 2015-09-01 | Mayo Foundation For Medical Education And Research | B7-H4 expression on tumor vasculature |
| US20080206235A1 (en) | 2006-12-27 | 2008-08-28 | Johns Hopkins University | Compositions and methods for stimulating an immune response |
| CN101951959A (zh) | 2007-11-30 | 2011-01-19 | 百时美施贵宝公司 | 抗b7h4单克隆抗体-药物缀合物和使用方法 |
| WO2009102820A2 (en) | 2008-02-11 | 2009-08-20 | Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services | Modified sugar substrates and methods of use |
| US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| MX368966B (es) | 2011-06-10 | 2019-10-23 | Mersana Therapeutics Inc | Conjugados de proteina-polimero-farmaco. |
| AU2012296613B2 (en) | 2011-08-15 | 2016-05-12 | Amplimmune, Inc. | Anti-B7-H4 antibodies and their uses |
| GB201115841D0 (en) | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| WO2013067492A1 (en) | 2011-11-03 | 2013-05-10 | The Trustees Of The University Of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
| BR112015014063A2 (pt) | 2012-12-19 | 2018-10-30 | Amplimmune Inc | anticorpos anti-b7-h4 humano e seus usos. |
| EA201591750A1 (ru) | 2013-03-14 | 2016-05-31 | Дженентек, Инк. | Антитела против b7-h4 и иммуноконъюгаты |
| US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| AU2014331714B2 (en) | 2013-10-11 | 2019-05-02 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EP3191518B1 (en) | 2014-09-12 | 2020-01-15 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
| US10626176B2 (en) | 2014-10-31 | 2020-04-21 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind B7-H4 |
| US9988661B2 (en) * | 2015-04-23 | 2018-06-05 | Synaffix B.V. | Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from A β(1,4)-N-acetylgalactosaminyltransferase |
| EP3414328B1 (en) | 2016-02-08 | 2024-01-10 | Synaffix B.V. | Enzymes for trimming of glycoproteins |
| KR102346988B1 (ko) | 2016-07-26 | 2022-01-03 | 시즈오카켄 | 항 b7-h4 항체 |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| WO2018195302A1 (en) | 2017-04-19 | 2018-10-25 | Bluefin Biomedicine, Inc. | Anti-vtcn1 antibodies and antibody drug conjugates |
| US10814011B1 (en) | 2017-06-16 | 2020-10-27 | Nantbio, Inc. | Anti-B7-H4 antibodies and methods |
| JP7437301B2 (ja) | 2017-08-25 | 2024-02-22 | ファイヴ プライム セラピューティクス インク | Ｂ７－ｈ４抗体及びその使用方法 |
| CN119097699A (zh) | 2018-01-23 | 2024-12-10 | 奈斯科尔公司 | B7-h4抗体及其使用方法 |
| MX2020008181A (es) | 2018-02-11 | 2020-09-18 | Jiangsu Hansoh Pharmaceutical Group Co Ltd | Anticuerpo anti-b7-h4, fragmento de union al antigeno y uso farmaceutico del mismo. |
| JP7258038B6 (ja) | 2018-02-21 | 2023-04-25 | ファイヴ プライム セラピューティクス インク | Ｂ７－ｈ４抗体の投薬計画 |
| WO2019165077A1 (en) | 2018-02-21 | 2019-08-29 | Five Prime Therapeutics, Inc. | B7-h4 antibody formulations |
| CN108948204B (zh) | 2018-06-15 | 2023-01-13 | 苏州旭光科星抗体生物科技有限公司 | 抗人b7-h4单克隆抗体、鉴定方法、应用和试剂盒 |
| CN113166242B (zh) | 2018-10-15 | 2024-11-19 | 戊瑞治疗有限公司 | 用于癌症的组合疗法 |
| MX2021004906A (es) | 2018-10-29 | 2021-09-10 | Mersana Therapeutics Inc | Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos. |
| MX2021014960A (es) | 2019-06-06 | 2022-03-04 | Shanghai Hansoh Biomedical Co Ltd | Conjugado de farmaco-anticuerpos anti-b7-h4 y uso medicinal del mismo. |
| BR112022013255A2 (pt) | 2020-01-09 | 2022-09-06 | Mersana Therapeutics Inc | Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo |
| US20230112085A1 (en) | 2020-01-30 | 2023-04-13 | Apeximmune Therapeutics Inc. | Anti-b7-h4 constructs and uses thereof |
| CN115298221A (zh) | 2020-03-18 | 2022-11-04 | 健玛保 | 结合b7h4的抗体 |
| AU2021248635A1 (en) | 2020-04-02 | 2022-10-27 | Mersana Therapeutics, Inc. | Antibody drug conjugates comprising STING agonists |
| US20230312722A1 (en) | 2020-06-30 | 2023-10-05 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-b7h4 antibody, and bispecific antibody and use thereof |
| WO2022147532A1 (en) | 2021-01-04 | 2022-07-07 | Mersana Therapeutics, Inc. | B7h4-targeted antibody-drug conjugates and methods of use thereof |
-
2022
- 2022-01-04 WO PCT/US2022/011119 patent/WO2022147532A1/en active Application Filing
- 2022-01-04 US US17/568,376 patent/US11964024B2/en active Active
- 2022-01-04 JP JP2023540678A patent/JP2024501894A/ja active Pending
- 2022-01-04 CA CA3203721A patent/CA3203721A1/en active Pending
- 2022-01-04 KR KR1020237025839A patent/KR20230137339A/ko active Pending
- 2022-01-04 AU AU2022205057A patent/AU2022205057A1/en active Pending
- 2022-01-04 EP EP22703107.7A patent/EP4271713A1/en active Pending
- 2022-01-04 TW TW111100248A patent/TW202241954A/zh unknown
- 2022-01-04 BR BR112023013263A patent/BR112023013263A2/pt unknown
- 2022-01-04 MX MX2023008000A patent/MX2023008000A/es unknown
-
2023
- 2023-07-02 IL IL304168A patent/IL304168A/en unknown
- 2023-07-03 CL CL2023001966A patent/CL2023001966A1/es unknown
- 2023-07-31 CO CONC2023/0010206A patent/CO2023010206A2/es unknown
-
2024
- 2024-03-05 US US18/595,834 patent/US20240269306A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI851552B (zh) | 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 | |
| AU2020203365B2 (en) | CD33 antibodies and use of same to treat cancer | |
| KR102084806B1 (ko) | 인테그린 αvβ6에 대한 항체 및 암을 치료하기 위한 그의 용도 | |
| JP2023129543A5 (enrdf_load_stackoverflow) | ||
| JP2019031565A5 (enrdf_load_stackoverflow) | ||
| EP2844675B1 (en) | Humanized pan-her antibody compositions | |
| JP2020509027A5 (enrdf_load_stackoverflow) | ||
| CN107735093A (zh) | Cd123抗体和其结合物 | |
| CN110022903B (zh) | Met抗体药物缀合物 | |
| JP2022169589A5 (enrdf_load_stackoverflow) | ||
| US20240092875A1 (en) | Sars-cov-2 antibodies for treatment and prevention of covid-19 | |
| ES2887343T3 (es) | Anticuerpos anti-GM-CSF y usos de los mismos | |
| JPWO2022147532A5 (enrdf_load_stackoverflow) | ||
| US20150110788A1 (en) | Bispecific antibodies with an fgf2 binding domain | |
| CN116997363A (zh) | 抗体药物偶联物治疗癌症的方法及用途 | |
| JP7130243B2 (ja) | 二重特異性抗体を用いた抗体薬物複合体プラットホーム | |
| CN112996540A (zh) | 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途 | |
| JPWO2020218951A5 (enrdf_load_stackoverflow) | ||
| CN113329769A (zh) | 具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物 | |
| WO2025061181A1 (en) | Anti-cdh17 antibodies and uses thereof | |
| WO2025117871A1 (en) | Bispecific tetravalent antibody targeting her2 and her3 | |
| WO2025072516A1 (en) | Methods of reducing weight loss using anti-gdf15 antibodies | |
| CN117597363A (zh) | 抗-tm4sf4人源化抗体及其用途 | |
| CN119701004A (zh) | 抗her2抗体药物偶联物治疗妇科恶性肿瘤的方法和用途 | |
| HK1100848B (en) | Anti-human tenascin monoclonal antibody |